Pts were defined as responders if they met the response criterion within the stated time frame, prior to any rescue or discontinuation. % = percent of pts meeting response criteria; ≥2 = at least 2 consecutive visits with CDAI ≤10; i-rate = exposure-adjusted incidence rate (% pts/month); N = number of randomised and treated pts; PBO = placebo treated pts in original study, Bari 4 mg treated pts in LTE. a RA-BUILD, b RA-BEACON.
Objectives: To characterize changes in absolute neutrophil counts (ANC), absolute leukocyte counts (ALC), and platelet counts following once daily oral administration of bari. Methods: Data were pooled from 6 placebo-controlled phase 2 and 3 studies of bari (2 and 4 mg). Changes in ANC, ALC, and platelets were evaluated for up to 52 weeks (wks) including data from a long-term extension study. Reversibility was evaluated in a subgroup of pts who discontinued treatment by wk 24. Results: Mean ANC decreased within 1 month of administration of bari, followed by stabilization and an increase to baseline after treatment discontinuation ( Figure  1 ). ANC <1000 cells/mm 3 were reported in <1% of pts, and 2 bari-treated pts (0.1%) reported permanent discontinuation of study drug due to neutropenia. Incidence of neutropenia was not associated with higher risk of overall or serious infections (Table 1) . Mean ALC increased within 1 month of bari administration and then decreased to baseline level in wks 12 to 24 (Figure 1 ). Lymphopenia appeared to be associated with slightly higher rate of overall infections (Table 1) . Mean platelet counts increased to peak at wk 2, returned towards baseline, stabilized over time, and returned to baseline after treatment discontinuation (Figure 1 ). Permanent study drug discontinuations from thrombocytosis occurred in 2 bari-treated pts (0.1%). No clear association between platelet increase and thromboembolic events was observed. Conclusions: Treatment with bari was associated with a decrease in ANC and an increase in ALC and platelets, which stabilized over time and returned to baseline with prolonged treatment (ALC) or treatment discontinuation (ANC and platelets). No associations between ANC decrease and infections or between thrombocytosis and thromboembolic events were observed. Background: Patient-provider discordance in assessment of disease status has been linked to lower patient satisfaction with potential implications on patient compliance and outcomes of care. Global assessment (GA) of disease activity in rheumatoid arthritis (RA) is discordant between patient and provider in about one third of cases. Prospective studies evaluating the implications of patient-provider discordance on RA disease course are lacking.
